Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

ID: 429614

(firmenpresse) - BUFFALO, NY -- (Marketwired) -- 10/27/15 -- (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and nine-month period ended September 30, 2015, and will host a conference call at 10:00 a.m. ET.

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at .

A replay of the call will be available starting on November 5, 2015, at 1:00 p.m. ET through November 19, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13622699. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at .



Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at .



Contact:
Rachel Levine
Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935




Email:

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Prima BioMed Gains Belgian Regulatory Approval to Commence a Registration Phase IIb Study of IMP321 iBio European Protein Expression Patent Emerges From Opposition Period
Bereitgestellt von Benutzer: Marketwired
Datum: 27.10.2015 - 12:00 Uhr
Sprache: Deutsch
News-ID 429614
Anzahl Zeichen: 0

contact information:
Town:

BUFFALO, NY



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 189 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5"
steht unter der journalistisch-redaktionellen Verantwortung von

Cleveland BioLabs, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cleveland BioLabs, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z